Mineralys Therapeutics announces new subgroup analyses from Phase 3 Launch-HTN trial evaluating blood pressure-lowering efficacy and safety of Lorundrostat ($33.12, 0.00)
StreetAccount Summary - Trading higher/lower: Japan mid-day
Akebia initiates Vafseo (vadadustat) post-marketing study in conjunction with large dialysis Organization ($3.72, 0.00)
Mitsubishi Chemical completes up-to-¥50B buyback (¥770.2000, -10.5)
Mitsubishi Chemical to transfer all stake in J-Film to Marunouchi Capital; terms undisclosed (¥784.3000, -42.9)
Mitsubishi Chemical reports Q1 net income attributable ¥19.63B vs year-ago ¥39.65B (¥814.4000, -12.8)
NewAmsterdam Pharma presents data from BROADWAY Trial demonstrating Statistically Significant Reductions in Alzheimer's Disease Biomarkers at AAIC 2025 ($22.78, 0.00)
StreetAccount Sector Preview - Japan Chemicals Apr-Jun Earnings
Mineralys Therapeutics announces Journal of the American Medical Association (JAMA) publication of results from pivotal Phase III Launch-HTN trial for Lorundrostat ($13.70, -0.01)
Mitsubishi Chemical resumed equal-weight at Morgan Stanley (¥744.0000, 0)
Powered by FactSet Research Systems Inc.